AAAAAA
Results:
1-7
|
Results: 7
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens
Authors:
Jahrsdorfer, B
Hartmann, G
Racila, E
Jackson, W
Muhlenhoff, L
Meinhardt, G
Endres, S
Link, BK
Krieg, AM
Weiner, GJ
Citation: B. Jahrsdorfer et al., CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens, J LEUK BIOL, 69(1), 2001, pp. 81-88
Authors:
Buban, GM
Link, BK
Doucette, WR
Citation: Gm. Buban et al., Influences on oncologists' adoption of new agents in adjuvant chemotherapyof breast cancer, J CL ONCOL, 19(4), 2001, pp. 954-959
Authors:
Vose, JM
Link, BK
Grossbard, ML
Czuczman, M
Grillo-Lopez, A
Gilman, P
Lowe, A
Kunkel, LA
Fisher, RI
Citation: Jm. Vose et al., Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, J CL ONCOL, 19(2), 2001, pp. 389-397
Authors:
Kostelny, SA
Link, BK
Tso, JY
Vasquez, M
Jorgensen, BH
Wang, H
Hall, WC
Weiner, GJ
Citation: Sa. Kostelny et al., Humanization and characterization of the anti-HLA-DR antibody 1D10, INT J CANC, 93(4), 2001, pp. 556-565
Authors:
Link, BK
Budd, GT
Scott, S
Dickman, E
Paul, D
Lawless, G
Fridman, M
Ford, J
Carter, WB
Citation: Bk. Link et al., Delivering adjuvant chemotherapy to women with early-stage breast carcinoma - Current patterns of care, CANCER, 92(6), 2001, pp. 1354-1367
Authors:
Davis, TA
Grillo-Lopez, AJ
White, CA
McLaughlin, P
Czuczman, MS
Link, BK
Maloney, DG
Weaver, RL
Rosenberg, J
Levy, R
Citation: Ta. Davis et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment, J CL ONCOL, 18(17), 2000, pp. 3135-3143
Authors:
Link, BK
Weiner, GJ
Citation: Bk. Link et Gj. Weiner, Monoclonal antibodies in the treatment of human B-cell malignancies, LEUK LYMPH, 31(3-4), 1998, pp. 237-249
Risultati:
1-7
|